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 Running head:  Adaptive Test for Additive Interaction 
 
Abbreviations: 
CML: constrained maximum likelihood;  
EB: empirical Bayes; 
GRS: genetic risk score;  
GWAS: genome-wide association studies; 
LRT: likelihood ratio test;  
MLE: maximum likelihood estimates; 
OCP: oral contraceptive pill; 
RERI: relative excess risk due to interaction;  
SNP: single nucleotide polymorphism;  
UML: unconstrained maximum likelihood; 
WGRS: weighted genetic risk score. 
 
 
 
ABSTRACT 
There have been recent proposals advocating the use of additive gene-environment interaction 
instead of the widely used multiplicative scale, as a more relevant public health measure. Using 
gene-environment independence enhances the power for testing multiplicative interaction in 
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case-control studies. However, under departure from this assumption, substantial bias in the 
estimates and inflated Type I error in the corresponding tests can occur. This paper extends the 
empirical Bayes (EB) approach previously developed for multiplicative interaction that trades 
off between bias and efficiency in a data-adaptive way, to the additive scale. An EB estimator of 
Relative Excess Risk due to Interaction is derived and the corresponding Wald test is proposed 
with general regression setting under a retrospective likelihood framework. We study the 
impact of gene-environment association on the resultant test with case-control data. Our 
simulation studies suggest that the EB approach uses the gene-environment independence 
assumption in a data-adaptive way and provides power gain compared to the standard logistic 
regression analysis and better control of Type I error when compared to the analysis assuming 
gene-environment independence. We illustrate the methods with data from the Ovarian Cancer 
Association Consortium. 
 
Keywords: Bias-Variance Trade-off, Effect Modification, Empirical Bayes, Genetic Risk Score, 
Relative Excess Risk, Shrinkage. 
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INTRODUCTION 
There has been an increasing interest in searching for gene by environment interaction (G x E) 
in the post genome-wide association studies (GWAS) era with limited success (1-5).  A number 
of methods have been proposed for efficient search of G x E effects that use the gene-
environment independence assumption (2, 6-10). Almost all of these studies have focused on 
testing/estimation of multiplicative interaction, perhaps due to the fact that standard logistic 
regression is the most commonly used tool for analyzing case-control data (11-13). However, it 
has been suggested in the literature that additive interaction is a more relevant public health 
measure (3, 14, 15). If the environmental exposure, say, E, can potentially be modified via an 
intervention, the additive gene x environment interaction measure can quantify the differences 
in the number of cases prevented if the intervention was offered in a prioritized way, across 
strata defined by genetic risk.  This characterization helps with policy questions when limited 
access to an intervention are available. Moreover, the additive measure of interaction 
corresponds more closely to the notion of mechanistic or causal measures of interaction (16, 
17).  
Although not commonly recognized, it is possible to test for additive interaction in a logistic 
regression model using case-control data. While a direct estimate of additive interaction on a 
risk difference scale cannot be obtained from case-control data, an alternative parameter, the 
relative excess risk due to interaction (RERI), can be represented in terms of relative risks.  
Assuming that the disease is rare, relative risks can be approximated by corresponding odds 
ratios and thus RERI can be viewed as a function of both main effects and multiplicative 
interaction parameters in a logistic regression model. Standard Delta theorem can be applied to 
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provide asymptotic variance and subsequently a Wald test for the null hypotheses RERI=0 can 
be conducted (18-20).  The fact that RERI=0 if and only if the additive null holds provides us a 
way to test for interaction on the additive scale by testing     RERI=0. More recently, Han et.al 
(21) developed a likelihood ratio test (LRT) for     RERI=0, applying the retrospective likelihood 
framework proposed by Chatterjee and Carroll (22) that permits the incorporation of the G-E 
independence assumption, and leads to a more powerful test than the previously proposed 
Wald test, in modest sample sizes, for both the unconstrained and constrained ML method. 
However, it is not clear how to extend the LRT in an EB-type adaptive framework and thus we 
proceeded with combining estimates of RERI instead of deriving a combination LRT.  
In this paper, we first consider the binary G, E scenario to illustrate our method for testing 
additive interaction in case-control studies. We provide closed form expressions of the 
maximum likelihood estimates (MLE) and Wald test of the RERI parameter without 
(unconstrained MLE) and with assuming gene-environment independence (constrained MLE). 
We then extend the empirical Bayes-type shrinkage approach for multiplicative G x E 
interaction proposed by Mukherjee et.al (6) to estimate RERI and test for additive interaction. 
An adaptively weighted estimator of RERI that combines the constrained and unconstrained 
estimators is proposed to trade-off between bias and efficiency. Finally, we extend the method 
to handle a completely general regression setting using the retrospective profile likelihood 
based framework in (22).  We conduct a simulation study to compare the performance of 
various tests and illustrate our method by applying it to study the interaction between oral 
contraceptive pill (OCP) use and previously identified genetic factors in a large consortium of 
case-control studies of ovarian cancer. 
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 METHODS 
We first consider a simple setup of an unmatched case-control study with a dichotomous 
genetic factor G and a dichotomous environmental exposure E. Let E=1 (E=0) denote an 
exposed (unexposed) individual and G=1 (G=0) denote whether an individual is a carrier (non-
carrier) of the susceptible genetic marker. Let D denote the disease status, where D=1 (D=0) 
stands for an affected (unaffected) individual. Let   and   be the number of selected controls 
and cases, respectively. The data can be represented in the form of a 2×4 table as displayed in 
Web Appendix 1. 
Let                      and                      denote the vector of observed cell 
frequencies in the controls and the cases, respectively. Let            denote the frequency 
of G=1 and            denote the frequency of E=1 among controls. Let 
                     and                      denote the true population parameters of 
the cell probabilities corresponding to a particular G-E configuration in the underlying control 
and case populations respectively. Let            denote the marginal prevalence of G=1 
among controls and            denote the marginal prevalence of E=1 among controls. 
The observed vectors of the cell counts can be viewed as random draws from two independent 
multinomial distributions in controls and cases respectively, namely,    Multinomial         
and    Multinomial       .  
Let us introduce the following notation for the key parameters of interest. Let     
             
             
             
             
⁄                denote the odds ratio associated with E for 
non-susceptible individuals (G=0),     
             
             
             
             
⁄                
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denote the odds ratio associated with G for unexposed individuals (E=0) and      
             
             
             
             
⁄                denote the joint odds ratio associated with the 
sub-group G=1 and E=1 compared to the reference group of G=0 and E=0. The multiplicative 
interaction parameter  is defined as: 
  
    
      
 
            
            
 
      
      
        
              
       
      
  
The parameter      represents the log odds ratio between G and E among the controls, 
characterizing the gene-environment association. In the additive scale, the measure of 
interaction is defined as: 
           [                             ]
 [                             ]
 [                             ] 
 
                                             
                   (1)      
Dividing (1) throughout by                we obtain a new measure relative excess risk 
due to interaction (RERI) 
                                                                     .         (2) 
When the disease is rare, OR approximates RR. Hence, we have  
                     .          (3) 
Note that by (1) and (3), testing                is equivalent to testing            , 
which is typically translated into              in a case-control study as described in 
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VanderWeele (23). After defining the above relevant parameters of interest, we use the 
definition of RERI in equation (3) in terms of ORs to proceed with inference under case-control 
sampling assuming the disease is rare for all configurations of G and E. 
Unconstrained maximum likelihood estimation 
The unconstrained maximum-likelihood (UML) estimate for all OR parameters mentioned 
above are obtained by simply substituting     with its MLE,  ̂           , implying, 
               ̂    
  ̂  
  ̂   ̂ 
 
            
            
,            ̂   
           ̂      ∑ ∑
 
   
 
   
 
    
The G-E association log odds ratio in controls can also be estimated as  ̂      
      
      
.  
The UML estimate of RERI can be easily obtained by plugging the corresponding estimated ORs 
in an unconstrained model into equation (3) and by the invariance property of MLE, serves as a 
consistent and asymptotically unbiased estimate of RERI regardless of the gene-environment 
independence assumption.  
    ̂    
      
      
 
      
      
 
      
      
      (4) 
Note that    and    are realizations from two independent multinomial distributions, and we 
can employ Delta method (Web Appendix 2) to obtain the asymptotic variance of     ̂   , 
which is the same as noted in (17-19). The Wald test for interaction is based on the 
standardized Z statistic           ̂    √   ̂(    ̂   )  which follows a N (0,1) distribution 
under the null RERI=0. 
Constrained maximum likelihood estimation OR
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Under G-E independence among controls, i.e.       and rare disease assumptions, Zhang 
et.al (24) proposed the constrained MLEs (CML) for    and    as follows: 
 ̂   
                  
  
    
 ̂   
                  
  
   ̂   
                  
  
   ̂   
                  
  
  and  ̂   
   
  
          . 
We obtain the corresponding OR estimates by substituting     with its constrained MLE under 
G-E independence,  ̂  
            
            
    ̂  
            
            
 ,  ̂   
                     
                     
 and 
 ̂    
      
      
,  ̂   
           ̂      ∑
 
   
 
   . Note that the estimated multiplicative 
interaction parameter ̂  is a function of only   , and is identical to the case-only estimator. 
The CML estimate of RERI can be computed by plugging the estimated ORs under the constraint 
into equation (3). Formally, the CML estimator for RERI is given by 
    ̂    
                     
                     
 
            
            
 
            
            
      (5) 
Under G-E independence assumption among controls, the CML estimator is consistent and 
asymptotically unbiased for the true RERI parameter. It is more precise than the UML estimator 
of RERI in equation (4) based on our simulations. The asymptotic variance of the CML estimator 
can also be approximated by Delta method, which is shown in Web Appendix 3. The Wald test 
for RERI in a constrained model again uses the standardized Z statistic          ̂    
√   ̂(    ̂   ) , and the power of the test is slightly lower than LRT for additive interaction in 
(21) as will be illustrated through our simulations. Under violation of gene-environment 
independence assumption,      , the CML estimate is asymptotically biased for the true 
RERI parameter and the tests are invalid. 
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 Empirical Bayes estimation 
Mukherjee et.al (6) proposed an empirical Bayes (EB) estimator of the multiplicative interaction 
which shrinks the UML and CML estimators in a data-adaptive way. It relaxes G-E independence 
assumption and makes a trade-off between bias and efficiency. Formally, the EB estimator of 
multiplicative interaction is given by  
     ̂    
 ̂   
 
 ̂  
   ̂   
      ̂     
 ̂  
 
 ̂  
   ̂   
      ̂         (6) 
where ̂     
      
      
 ,  ̂     
            
            
  ,  ̂   
  ∑ ∑
 
   
 
   
 
    and  ̂      
      
      
.  
We employ the same idea of adaptive weighting and propose the EB estimator for RERI as, 
    ̂   
     ̂        ̂    
 
   ̂     ̂          ̂        ̂     
    ̂    
   ̂     ̂    
   ̂     ̂          ̂        ̂     
    ̂        
     ̂          ̂        ̂           (7),  
where       ̂ ̂     is a shrinkage factor of the same form as defined in Chen et.al (25) 
with   ̂      ̂        ̂    and      ̂(    ̂   ) . To explain the intuitive rationale 
behind the estimator, observe that as    ̂   , i.e. as the data provide the evidence in favor of 
G-E independence,      ̂        ̂      , the estimator puts more weight on CML 
estimator to gain more efficiency, and as    ̂   . i.e. as the G-E dependence becomes 
stronger in control population,     ̂        ̂    becomes larger, then the EB estimator puts 
more weight on UML estimator to reduce bias.  In large samples, the EB estimator converges to 
the UML estimate and thus is asymptotically unbiased for the true RERI parameter (6). The 
asymptotic variance of     ̂   is derived by Delta method (See Web Appendix 4), assuming 
   ̂(    ̂   ) as a constant relative to the order of magnitude of the point estimates (6). We 
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use Wald test for the EB estimator based on the standardized Z statistic          ̂   
√   ̂(    ̂  ) .  
Remark 1. We also considered two other forms of adaptive weights. One is to modify the 
shrinkage factor K in (7) and let   ̂   ̂   instead of      ̂        ̂   , namely,      ̂     
    ̂     
      ̂        ̂    , where 
   (    ̂  ̂
 
)
  
. The other is to plug in the 
EB estimates,   ̂  , obtained from using the retrospective likelihood framework in (6) as 
implemented in R package CGEN (6, 22, 25) directly into equation (3), namely,     ̂    
  ̂     ̂    ̂   , where all estimated ORs are EB estimates proposed under the 
multiplicative model. The EB estimator we proposed in equation (7) demonstrates superior 
performance among the three choices, based on our simulation study.  
Remark 2:  As shown in Chen et.al (25), the asymptotic theory for CML and consequently EB is 
non-regular under the independence assumption. The Delta method does not technically apply 
for estimating the asymptotic variance. Theoretically, the test statistic also fails to be 
asymptotically normal under G-E independence (25, 26).  However, in practice, the estimated 
variance derived by the Delta Method approximates the empirical variance very well as noted 
in the simulation studies (see Web Appendix 5, Web Tables 1-2 and Web Figures 1-2). Under G-
E dependence, EB estimate converges in large sample to UML estimate and thus to the true 
RERI parameter and standard likelihood asymptotics holds (6). 
Profile likelihood framework for general regression setting 
Consider the retrospective likelihood considered in Chatterjee and Carroll (22), Mukherjee et.al 
(6) and as implemented in the R package CGEN: 
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∑                              
                       
The three ingredients of the above retrospective likelihood are: 
(a) The logistic regression disease risk model of interest with multiplicative GEI parameter: 
                                        
  , where   denotes other 
covariates.  
(b)                           
  .  While this is the gene model used for UML, allowing 
G-E dependence, in the CML method,          reduces to        under the assumption of G-
E independence conditional on  , implying        .  
(c) The distribution        is allowed to be completely non-parametric. We then maximize the 
retrospective likelihood using existing routines in CGEN to obtain   ̂          ̂    , the vector of 
all the parameter estimates of the disease risk model in (a), namely,                  . 
When it comes to defining RERI with a general G and E variable adjusting for covariates Z,  
particularly with case-control data, as described in VanderWeele (23), let us denote by 
                    the relative excess risk due to interaction by replacing risk ratios with 
corresponding  odds ratios in the RERI expression in (3) as typically done in a case-control study. 
With general continuous and ordinal exposures one has to consider the magnitude of change in 
exposure for which one is examining the interaction. Let us consider the situation when 
environmental risk factor changes from    to    and genetic risk factor changes from    to    
but other covariates   are held constant. Formally, it is defined as 
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                                    (9) 
This last approximation of risk ratios by odds ratios holds when the outcome is rare in each 
stratum defined by the two exposures or when controls are selected from the entire population, 
not just the non-cases (27). More generally, if G and E are both categorical factors with I and J 
levels with coefficients corresponding to different levels of each factor, then           in 
equation (9) become (I-1), (J-1) and (I-1)(J-1) dimensional vectors instead of scalars. Note that 
    ̂       ̂      and     ̂       ̂     , can be viewed as function of UML and CML 
estimates of relative risk parameters, where f is the function in equation (9). The variance of 
    ̂    and     ̂    can be calculated by Delta method. The EB estimator of RERI is same as 
in equation (7) and its estimated variance is calculated by Delta method using the joint 
distribution of   ̂     ̂     as proposed by Mukherjee et.al (6) (Web Appendix 6). The Wald 
tests for the three estimators are all based on the standardized Z statistic. We have provided 
general codes to test for RERI at (28).  
 
Example: Analysis of G x E interactions in case-control studies of ovarian cancer 
Epithelial ovarian cancer is one of the most common malignancies of the female reproductive 
tract. Approximately 14,240 women died from ovarian cancer in 2016 in the United States, 
causing more deaths than any other cancer of the female reproductive system. There are 
several well-established non-genetic risk factors for ovarian cancer (29-35), and recent genome-
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wide association studies have identified and replicated 18 variants that influence disease risk 
(36). To this end, the Ovarian Cancer Association Consortium (OCAC) has undertaken an effort 
to study interactions focusing on the 18 confirmed single nucleotide polymorphisms (SNPs) and 
seven well-established risk factors: race, history of endometriosis, first degree family history of 
ovarian cancer, oral contraceptive pill (OCP) use, parity, tubal ligation, and age. In our 
illustrative analysis, we focus on OCP x SNP interaction and use genetic data from 15 OCAC 
studies that also have data on epidemiologic risk factors. 
Each SNP is coded as the number of risk alleles a subject carried and all subsequent analysis 
assumed this additive genetic susceptibility model. Published ORs of the 18 confirmed loci in 
Web Table 3 are from analyses presented in Collaborative Oncological Gene-Environment Study 
(37-44). As a parsimonious and succinct way of summarizing the effects of genetic variants 
across all loci for each subject, we construct a "genetic risk score" (GRS) variable as the sum of 
the risk allele counts across all loci and a “weighted genetic risk score” (WGRS) as the weighted 
sum, where the weight for each individual SNP is determined by the published log OR in large 
meta-analysis. Polygenic risk scores have been used for risk stratification in multiple G x E 
papers recently (3,45). Analysis of marginal effect for GRS and WGRS is shown in Web Table 4. 
Each environmental factor is coded as a categorical variable as described in Web Table 5. The 
merged G × E dataset has a sample size of 11,661 subjects with European ancestry, with 4,135 
cases and 7,526 controls from 13 study sites (Web Table 6). 
To illustrate our inference for interactions between OCP use (1 =ever and 0 =never) and genetic 
risk factors we consider both single SNP x OCP and (W)GRS x OCP interaction. For single SNP 
analysis, we consider the top two hits in the 18 confirmed loci, i.e. rs62274042 (SNP1) and 
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rs10962691 (SNP2) as reported in Web Table 3. We used additive coding for our SNP x OCP 
analysis. For GRS and WGRS, we use the quartiles in controls to define a categorical variable 
with four categories. The analysis model adjusts for study site and all other environmental risk 
factors except race. 
 
Simulation design 
In our simulation study, we first investigate the Type I error, standard power at level   and 
power at empirical   (empirical Type I error is used to report power in situations where Type I 
error is not maintained) of Wald tests for     ̂        ̂    and     ̂   under various 
alternative values of RERI across a spectrum of scenarios, varying the strength of G-E 
association, main effects of G and E, minor allele frequency of G, prevalence of exposure E, test 
size and sample sizes. We compare the power of Wald test for     ̂    with the previously 
proposed LRT for additive interaction under G-E independence (21). We also explore estimation 
properties like the absolute relative bias and MSE of the three estimators as well as those of 
two alternative proposals,     ̂    and     ̂   . Note that both RERI and multiplicative 
interaction parameters are obtained from the underlying true logistic regression model  
                                                                 ,  
where RERI=                                ,  and     (   ), so that the 
value of RERI is well-defined given   and vice versa, once the main effect parameters 
            and              are specified.  
We set prevalence of G and E in controls,                  and                 ; the main 
effects                  ;                   ; sample size                   ; 
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size of test                ; the strength of G-E association,         , change from 0.8 to 
1.2 at a grid of 0.1 and RERI change from 0 to 1.5 with a grid of 0.1. The number of simulated 
datasets is 1000 when        and is 106 when         . The population parameters of 
cell probability    and    are defined by solving the equations in Web Appendix 7 (9, 46): 
We generate data independently from the two multinomial distributions corresponding to the 
case and control populations, according to the above probabilities with number of cases and 
control as     , respectively. We also considered another simulation setting to mimic a large-
scale genomewide search of interactions where we use random distribution for the parameters 
corresponding to the set of null markers. We first compute the UML, CML and EB estimators 
using equations (4), (5), and (7) and then compare their Type I error, power, power at empirical 
  , absolute relative bias and MSE. Type I error over 1000 replications. Power are estimated by 
the proportion of null hypothesis          rejected at the given level of significance  , i.e. 
the proportion of times    >       , where Z is Wald test statistic.  Power at empirical   is a 
modified power which utilizes an empirical P value threshold as the rejection rule to control the 
Type I error around the given significance level when the Type I error at the desired nominal 
level is not maintained. The absolute relative bias is calculated by averaging |    ̂      | 
     and MSE is calculated by averaging (    ̂      )
 
.  
RESULTS 
Ovarian cancer data example 
The distributions of GRS and WGRS in cases and controls are displayed in Web Figure 3. Relative 
to the control distributions, the upper tails of the case distributions are shifted slightly 
rightward. We calculate UML, CML and EB estimators of interactions in both multiplicative and 
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additive scale. The estimates, corresponding CIs and P-values of Wald test are shown in Table 1. 
In SNP1×OCP analysis, the strength of G-E association is modest: exp     =1.07 (95% CI 
[0.94,1.21]), EB estimate of RERI is -0.16 with 95% CI [-0.50,0.18], where the weight on 
    ̂    is 43%. In SNP2×OCP analysis, the G-E association seems weaker with exp     =0.96 
(95% CI [0.83,1.11]). EB estimate of RERI is 0.04 with 95% CI [-0.11,0.18], with its weight on 
    ̂    decreasing to 11%. The confidence intervals corresponding to     ̂   are narrower 
compared to the corresponding intervals for      ̂   . The point estimate     ̂   lies 
between     ̂    and     ̂   , reflecting the combined efficiency-robustness feature of the 
EB estimator. In WGRS×OCP analysis we report interactions associated with a change of OCP 
from 0 to 1 (ever users to never users) and WGRS from the lowest to the highest quartile (as 
defined through distribution of WGRS in controls) the multiplicative measure of interaction ̂   
is not significant at α=0.05 but     ̂   departs from 0 significantly with EB estimate of RERI -
0.52(95% CI [-0.91, -0.13]) and has a very small P-value, 0.009. 
To visually present the results, we fit a standard logistic regression model including the main 
effects of OCP use and quartiles of WGRS as a categorical factor, and an interaction term for 
WGRS×OCP adjusting for study sites and other risk factors. Figure 1 shows the odds ratio of OCP 
and corresponding CI stratified by WGRS. The odds ratio of OCP is 0.61 (0.50,0.74) in the lowest 
WGRS quartile and 0.51 (0.43,0.60) in the highest quartile. The overlapping CIs indicate a non-
significant multiplicative interaction. Additionally, if we assume that approximately 1.3 percent 
of women will be diagnosed with ovarian cancer at some point during their lifetime (47) and 70% 
women will use OCP at some point in their life in this population (estimated from the OCAC 
data), we present the estimated lifetime risk of ovarian cancer and corresponding 95% CI within 
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each WGRS stratum in Figure 2, for OCP users and non-users. Estimates of lifetime absolute risk 
for OCP users is 0.75% (0.57%, 0.98%) and 1.23% (1.00%, 1.51%) for OCP non-users in the 
lowest WGRS stratum with a difference of 0.48% (0.02%, 0.94%) and the corresponding 
numbers were 1.40% (1.08%, 1.81%) and 2.72% (2.05%, 3.60%) with a difference of 1.32% 
(0.24%, 2.52%) for subjects in the highest WGRS stratum, showing why the test for RERI is 
significant.   
Results from the Simulation Study 
Type I error. Web Table 7 presents Type I errors for different tests of RERI. One can observe that 
UML maintains nominal level α across different choices of     . An inflated Type I error 
associated with CML is observed when G-E independence assumption is violated. EB test is valid 
when exp     =1 and has a modest inflation on Type I error when G is associated with E. The 
maximal observed Type I error of EB at α=0.05 is 0.099 when sample size is 40,000, test size is 
0.05 and         =1.1. Web Figure 4 presents how Type I error varies with exp      for the 
three estimators. The Type I error of CML is very sensitive to the G-E association but the 
performance of EB is relatively robust with marked reduction in Type I error compared to CML. 
The findings remain similar for different choices of    ,   ,    and     (Web Tables 8-9). 
Results from additional simulation mimicking a Genomewide Association Study: To justify the 
use of EB estimator in genomewide assessment of G-E interaction, we conduct another 
simulation study similar to that in Reference (8), which generates 2000 cases and controls with 
1 causal marker together with M-1 null markers where M is 10,000. G-E independence 
parameter     in controls have a random mixture distribution with point mass around 
independence and      is the proportion of null loci that follow G-E independence. The detailed 
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simulation setting is presented in Web Appendix 8. The expected nominal level for both 
familywise error rate and expected number of false positives is 0.05 when G-E independence 
holds. However, if there is G-E dependence for a proportion of markers, Bonferroni correction 
cannot guarantee the nominal level for EB and CML.  As shown in Table 2, when 99% of the 
markers are independent, EB maintains familywise Type I error rate of 0.06 and expected 
number of false positives of 0.06.  The performance of CML is significantly worse with 
familywise error rate of 99% and expected number of false positives 3.76. 
Power. Figure 3 shows the power curves of Wald test for three estimators with         
  under different strengths of G-E association (Web Tables 10-15). It is hard to compare the 
estimated powers directly from the figure as the inflated Type I error of CML and EB leads to 
the misleading high power values. Hence, we assess the power at empirical   for CML and EB, 
which controls the corresponding Type I error at 0.05. UML is the most efficient when 
exp(   )=0.8, CML is the most efficient when exp(   )=1 and 1.2, and EB power always lies in 
between. For a sample numerical comparison, let us compare the powers of the three 
approaches at RERI=0.5 to represent one typical scenario. When exp     =0.8, the empirical 
power of EB (0.275) is 41% lower than UML (0.672), meanwhile CML has nearly 0 power. When 
exp     =1, the empirical power of EB (0.870) is 25% higher than UML (0.693) but 10% lower 
than CML (0.970). When exp     =1.2, the empirical power of EB (0.718) is slightly higher than 
UML (0.714) but 28% lower than CML (0.993). We then compare the power of Wald test for 
    ̂    with LRT for additive interaction shown in Web Figure 5. The power of LRT is uniformly 
slightly higher than the Wald test with true value of RERI varying from 0 to 0.5 with a grid of 0.1. 
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Absolute relative bias and MSE results are relegated to Web Appendix 9, Web Tables 16-19, 
Web Figure 6. 
 
 
 
DISCUSSION 
In this paper, we extend the EB estimator of gene-environment interaction proposed earlier on 
the multiplicative scale to additive scale in case-control studies. The EB estimator exploits G-E 
independence assumption to perform a trade-off between bias and efficiency. The simulation 
study showed that the test based on the EB estimator can provide a good control of Type I error 
and it is always intermediate between UML and CML with respect to power, relative bias and 
mean squared error. In the ovarian cancer data example, we conducted a (W)GRSOCP analysis 
to illustrate the application of the proposed method. We found a significant additive 
(W)GRS×OCP interaction but insignificant multiplicative interaction at =0.05. 
As an inherent limitation of case-control studies, only the relative risk can be estimated, e.g. 
RERI, instead of the underlying direct measure, e.g.           in equation (1), because     can 
only be estimated from cohort data. However, general population incidence data from cohort 
studies can be combined with case-control risk-factor models to estimate absolute risks in 
population-based case-control studies (48), as we carried out in Figure 2. If the rare disease 
assumption for each configuration of G and E does not hold, approximating RR by OR in case-
control studies will not be accurate and thus the proposed estimate of RERI may depart from 
the truth. By using the retrospective maximum likelihood estimates, using prior guesses for 
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disease prevalence and adaptive combinations like EB procedure we can make our inference 
less biased under violation of the rare disease and gene-environment independence 
assumptions. 
There is increasingly more interest in inference for additive interaction using case-control data. 
Tchetgen –Tchetgen et.al (49) described a general approach to test for G x E additive 
interaction exploiting G-E independence which is robust to possible misspecification of main 
effects in the outcome regression. Han et.al (50) proposed a score test for UML and CML 
estimators of genetic associations under the additive null. In the future, it is of analytical 
interest to establish an EB version of adaptive score test and adaptive LRT as most of the recent 
work has been in terms of combining estimators but not tests.  
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Table 1.  Estimates and 95% confidence interval corresponding to SNP/GRS x Oral Contraceptive 
Pill Use Interaction under Both Multiplicative and Additive Scale with accompanying P-values 
from Wald Tests 
 
Interaction Multiplicative ( ) Additive (RERI) 
SNP1a OCPb Estimatec  95% CI P-value Estimated 95% CI P-value 
UML 0.94 0.73, 1.22 0.645 -0.25 -0.60, 0.10 0.162 
CML 1.06 0.88, 1.28 0.548 -0.09 -0.33, 0.14 0.432 
EB 1.00 0.78, 1.29 0.970 -0.16 -0.50, 0.18 0.348 
SNP2a OCP         
UML 0.93 0.82, 1.05 0.255 0.08 -0.18, 0.34 0.552 
CML 0.94 0.85, 1.04 0.224 0.03 -0.18, 0.25 0.757 
EB 0.94 0.85, 1.04 0.222 0.04 -0.11, 0.18 0.598 
GRSd OCP         
UML 0.82 0.65, 1.02 0.073 -0.64 -1.01, -0.27 0.001 
CML 0.92 0.77, 1.08 0.305 -0.43 -0.68, -0.18 0.001 
EB 0.86 0.69, 1.07 0.197 -0.54 -0.93, -0.16 0.005 
WGRSd OCP         
UML 0.90 0.76, 1.06 0.212 -0.61 -0.99, -0.23 0.002 
CML 0.95 0.83, 1.08 0.417 -0.40 -0.67, -0.14 0.003 
EB 0.93 0.81, 1.08 0.366 -0.52 -0.91, -0.13 0.009 
 
Abbreviations: CML, constrained maximum-likelihood; EB, empirical Bayes; GRS, genetic risk 
score; RERI, relative excess risk due to interaction; UML, unconstrained maximum-likelihood; 
WGRS, weighted genetic risk score. 
a SNP1 denotes rs62274042 and SNP2 denotes rs10962691. Marginal disease odds ratios 
corresponding to these SNPs are 1.45 (1.37, 1.54) and 1.25 (1.20, 1.30) respectively. 
b OCP=1 if the individual ever used OCP and OCP=0 if never. 
c The analysis is based on subjects with European ancestry, using data on 4,135 cases and 7,526 
controls from 13 study sites from the Ovarian Cancer Association Consortium. The model 
adjusts for history of endometriosis, first degree family history of ovarian cancer, parity, tubal 
ligation, age and study site.  
d (W)GRS is a categorical variable defined by quartiles of WGRS in controls, e.g. (W)GRS=3 if it is 
above the 75th percentile in controls and (W)GRS=0 if it is below the 25th percentile in controls. 
The minimal, 25th, 50th, 75th percentiles and the maximum are 3, 11, 12, 14 ,22 for GRS and 0.32, 
1.33, 1.53, 1.75 and 2.86 for WGRS. In this table, we only present the coefficient of the 
interaction term corresponding to a change of OCP from 0 to 1 and of WGRS from 0 to 3. 
  
OR
IG
IN
AL
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
 
Downloaded from https://academic.oup.com/aje/article-abstract/doi/10.1093/aje/kwx243/3867974/Robust-Tests-for-Additive-Gene-Environment
by University of Cambridge user
on 12 September 2017
Table 2. Empirical Familywise Type I Error Rate at 5% overall level of significance, and Expected 
Number of False Positives corresponding to UML, CML and EB Wald Tests  
 
 Proportion of markers satisfying gene-environment 
independence (    ) 
a 
0.95 0.99 0.995 0.9975 0.9995 1.00 
Empirical Familywise Type I error b 
UML 0.084 0.072 0.062 0.071 0.041 0.058 
CML 1.000 0.994 0.966 0.745 0.874 0.064 
EB 0.138 0.056 0.045 0.038 0.042 0.035 
Expected number of false positives c 
UML 0.085 0.073 0.062 0.071 0.042 0.059 
CML 23.451 3.761 2.814 1.050 0.937 0.067 
EB 0.150 0.060 0.045 0.039 0.044 0.035 
 
Abbreviations: CML, constrained maximum-likelihood; EB, empirical Bayes; RERI, relative excess 
risk due to interaction; UML, unconstrained maximum-likelihood. 
a The population-level G-E association structure among null loci is assumed to be of the form of 
a mixture distribution reflecting that a large fraction, i.e.,     , of the SNPs, indeed, are 
independent of E in the population, whereas the remaining          of SNPs show some 
departures from the independence assumption following a N (0, sd=log(1.5)/2) distribution. 
b  The Wald test is for RERI=0 under a large-scale genomewide G x E scan simulation scenario 
with 10000 markers and 2000 cases and controls. Empirical familywise type I error is estimated 
as the empirical proportion of data sets declaring at least 1 null marker to be significant using 
level of significance α/10000.  This estimates the probability of at least one false positive under 
the global null.  
c Expected number of false positives is estimated as the average number of falsely rejected null 
hypotheses, averaged over 1000 data sets. 
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Figure 1. Odds ratio of oral contraceptive pill and corresponding 95% CI within each quartile of 
the weighted genetic risk score. The odds ratios are estimated from a standard logistic 
regression adjusting for history of endometriosis, first degree family history of ovarian cancer, 
parity, tubal ligation, age and study site. 
 
Figure 2. Predicted probability of ovarian cancer and corresponding 95% CI within each quartile 
of the weighted genetic risk score comparing oral contraceptive pill users and non-users. The 
relative risk parameters are obtained from a standard logistic regression model adjusting for 
history of endometriosis, first degree family history of ovarian cancer, parity, tubal ligation, age 
and study site. We assume that approximately 1.3 percent of women will be diagnosed with 
ovarian cancer at some point during their lifetime and 70% women will use oral contraceptive 
pill at some point in their life. The predicted probabilities are estimated by fixing other 
covariates at their most frequent value. 
Figure 3. Power curves of unconstrained maximum-likelihood (UML), constrained maximum-
likelihood (CML) and empirical Bayes (EB) Wald test for relative excess risk due to interaction 
(RERI) under different strength of G-E association:  data are generated on 4000 cases and 4000 
controls with fixed parameters       ,       ,        ,       . RERI changes from 
0 to 1.5 with a grid level of 0.1, corresponding multiplicative interaction changes from 0.94 to 
1.78. The top panels (A, B, C) correspond to the raw power, whereas the bottom panels (D, E, F) 
correspond to the power at empirical  . The left, center, and right panels correspond to 
different values of the G-E association odds ratio, i.e. exp(   )=0.8, 1.0, 1.2. 
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